187 related articles for article (PubMed ID: 17497245)
1. Selectivity determinants of the aldose and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Podjarny A
Cell Mol Life Sci; 2007 Aug; 64(15):1970-8. PubMed ID: 17497245
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
3. Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductase.
Carbone V; Zhao HT; Chung R; Endo S; Hara A; El-Kabbani O
Bioorg Med Chem; 2009 Feb; 17(3):1244-50. PubMed ID: 19121944
[TBL] [Abstract][Full Text] [Related]
4. All in the family: aldose reductase and closely related aldo-keto reductases.
Petrash JM
Cell Mol Life Sci; 2004 Apr; 61(7-8):737-49. PubMed ID: 15094999
[TBL] [Abstract][Full Text] [Related]
5. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
El-Kabbani O; Old SE; Ginell SL; Carper DA
Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
7. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
8. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
[TBL] [Abstract][Full Text] [Related]
9. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
10. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
[TBL] [Abstract][Full Text] [Related]
11. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
Steuber H; Heine A; Podjarny A; Klebe G
J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
[TBL] [Abstract][Full Text] [Related]
12. Probing the inhibitor-binding site of aldose reductase with site-directed mutagenesis.
Hohman TC; El-Kabbani O; Malamas MS; Lai K; Putilina T; McGowan MH; Wane YQ; Carper DA
Eur J Biochem; 1998 Sep; 256(2):310-6. PubMed ID: 9760169
[TBL] [Abstract][Full Text] [Related]
13. Potent and selective inhibition of the tumor marker AKR1B10 by bisdemethoxycurcumin: probing the active site of the enzyme with molecular modeling and site-directed mutagenesis.
Matsunaga T; Endo S; Soda M; Zhao HT; El-Kabbani O; Tajima K; Hara A
Biochem Biophys Res Commun; 2009 Nov; 389(1):128-32. PubMed ID: 19706287
[TBL] [Abstract][Full Text] [Related]
14. In Search of Differential Inhibitors of Aldose Reductase.
Balestri F; Moschini R; Mura U; Cappiello M; Del Corso A
Biomolecules; 2022 Mar; 12(4):. PubMed ID: 35454074
[TBL] [Abstract][Full Text] [Related]
15. Aldose Reductase and the Polyol Pathway in Schwann Cells: Old and New Problems.
Niimi N; Yako H; Takaku S; Chung SK; Sango K
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494154
[TBL] [Abstract][Full Text] [Related]
16. Kinetic characteristics of ZENECA ZD5522, a potent inhibitor of human and bovine lens aldose reductase.
Cook PN; Ward WH; Petrash JM; Mirrlees DJ; Sennitt CM; Carey F; Preston J; Brittain DR; Tuffin DP; Howe R
Biochem Pharmacol; 1995 Apr; 49(8):1043-9. PubMed ID: 7748183
[TBL] [Abstract][Full Text] [Related]
17. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of the 2-oxoaldehyde methylglyoxal by aldose reductase and by glyoxalase-I: roles for glutathione in both enzymes and implications for diabetic complications.
Vander Jagt DL; Hassebrook RK; Hunsaker LA; Brown WM; Royer RE
Chem Biol Interact; 2001 Jan; 130-132(1-3):549-62. PubMed ID: 11306074
[TBL] [Abstract][Full Text] [Related]
19. Benzoxazinone-thiosemicarbazones as antidiabetic leads via aldose reductase inhibition: Synthesis, biological screening and molecular docking study.
Shehzad MT; Imran A; Njateng GSS; Hameed A; Islam M; Al-Rashida M; Uroos M; Asari A; Shafiq Z; Iqbal J
Bioorg Chem; 2019 Jun; 87():857-866. PubMed ID: 30551808
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationship of 2-phenyliminochromene derivatives as inhibitors for aldo-keto reductase (AKR) 1B10.
Endo S; Hu D; Suyama M; Matsunaga T; Sugimoto K; Matsuya Y; El-Kabbani O; Kuwata K; Hara A; Kitade Y; Toyooka N
Bioorg Med Chem; 2013 Nov; 21(21):6378-84. PubMed ID: 24071447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
